For thousands of families living with the daily grind of type 1 diabetes, a quiet revolution has just arrived on the NHS.
Teplizumab, an immunotherapy drug, has been approved for use in Britain and could give children and adults at high risk of developing the condition up to three extra years before they need to start insulin injections. That’s not a small thing. For a teenager, three years is GCSEs, A-levels, a chunk of adolescence lived without finger-prick tests and pump alarms.
Type 1 diabetes affects around 400,000 people in the UK. Unlike type 2, it’s an autoimmune condition where the body attacks its own insulin-producing cells in the pancreas. There’s no cure, and until now, nothing that could meaningfully slow that process down.
Teplizumab works by targeting the immune cells responsible for the attack, essentially buying time for the pancreas to keep functioning. It’s given as a course of intravenous infusions over a couple of weeks, and clinical trials showed it delayed the onset of full-blown type 1 diabetes by a median of three years in people who were already showing early warning signs.
“This is the first treatment that actually changes the course of the disease rather than just managing the symptoms,” one diabetes specialist noted following the approval. “We’ve never had anything like this before.”
The drug will be available to people identified as being at high risk through screening, typically close relatives of those already diagnosed who test positive for specific antibodies. It won’t help everyone, and it’s not a cure. But it does open a door that’s been firmly shut for decades.
NICE confirmed the approval after reviewing the clinical evidence, and NHS England has confirmed it will be made available. Exactly how quickly it reaches patients, and how screening programmes will be scaled up to identify those who’d benefit, remains to be seen.
For parents who’ve watched their child receive a type 1 diagnosis and felt completely powerless, this matters enormously. The question now is whether the NHS can move fast enough to get it to the people who need it most.
